An Opportunity Missed: Biosimilars in the United States

被引：5
|
作者：
Goll, Guro L. [1 ]
Kvien, Tore K. [1 ]
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷 / 07期
关键词：
DOUBLE-BLIND; ORIGINATOR INFLIXIMAB; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; CT-P13; ARTHRITIS; EFFICACY; SAFETY; SWITCH;
D O I：
10.1002/art.41280
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1046 / 1048
页数：3
相关论文
共 50 条
  • [1] An opportunity not to be missed: The future of comparative law in the United States
    Mattei, U
    AMERICAN JOURNAL OF COMPARATIVE LAW, 1998, 46 (04): : 709 - 718
  • [2] INACTIVATED POLIO VACCINE FOR THE UNITED-STATES - A MISSED VACCINATION OPPORTUNITY
    PLOTKIN, SA
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (10) : 835 - 839
  • [3] The 1968 International Year for Human Rights: A Missed Opportunity in the United States
    Snyder, Sarah B.
    DIPLOMATIC HISTORY, 2018, 42 (05) : 831 - 858
  • [4] Israel, the United States, Saudi Arabia and the Fand Plan of 1961: an historic missed opportunity
    Bermant, Azriel
    BRITISH JOURNAL OF MIDDLE EASTERN STUDIES, 2023, 50 (04) : 1020 - 1038
  • [5] Pneumococcal Urinary Antigen Testing in United States Hospitals: A Missed Opportunity for Antimicrobial Stewardship
    Schimmel, Jennifer J.
    Haessler, Sarah
    Imrey, Peter
    Lindenauer, Peter K.
    Richter, Sandra S.
    Yu, Pei-Chun
    Rothberg, Michael B.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (06) : 1427 - 1434
  • [6] A Missed Opportunity to Address a National Shame: The Case of Sickle Cell Disease in the United States
    Freed, Gary L.
    JAMA PEDIATRICS, 2019, 173 (08) : 715 - 716
  • [7] Biosimilars in Oncology in the United States A Review
    Nabhan, Chadi
    Parsad, Sandeep
    Mato, Anthony R.
    Feinberg, Bruce A.
    JAMA ONCOLOGY, 2018, 4 (02) : 241 - 247
  • [8] Biosimilars: Are They Ready for Primetime in the United States?
    Hirsch, Bradford R.
    Lyman, Gary H.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (08): : 934 - 942
  • [9] Biosimilars in the United States: Emerging Issues in Litigation
    Alice Yuen-Ting Wong
    Martha M. Rumore
    Albert Wai-Kit Chan
    BioDrugs, 2017, 31 : 189 - 205
  • [10] Biosimilars And The European Experience: Implications For The United States
    Megerlin, Francis
    Lopert, Ruth
    Taymor, Ken
    Trouvin, Jean-Hugues
    HEALTH AFFAIRS, 2013, 32 (10) : 1803 - 1810
12345